{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:17:50Z","timestamp":1792531070236,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11864-022-00948-2","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T09:03:32Z","timestamp":1647507812000},"page":"562-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-6213","authenticated-orcid":false,"given":"Hisashi","family":"Kanemaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-2049","authenticated-orcid":false,"given":"Yukari","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7974-2565","authenticated-orcid":false,"given":"Akira","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3080-1621","authenticated-orcid":false,"given":"Ikko","family":"Kajihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-7682","authenticated-orcid":false,"given":"Satoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"19","key":"948_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm.2017.06.09","volume":"5","author":"I Arozarena","year":"2017","unstructured":"Arozarena I, Wellbrock C. Overcoming resistance to BRAF inhibitors. Ann Transl Med. 2017;5(19):387.","journal-title":"Ann Transl Med."},{"issue":"4","key":"948_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/cancers12040960","volume":"12","author":"M Boyer","year":"2020","unstructured":"Boyer M, Cayrefourcq L, Dereure O, Meunier L, Becquart O, Alix-Panabi\u00e8res C. Clinical relevance of liquid biopsy in melanoma and Merkel cell carcinoma. Cancers. 2020;12(4):960.","journal-title":"Cancers."},{"issue":"2","key":"948_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/ijms21020432","volume":"21","author":"K Wakamatsu","year":"2020","unstructured":"Wakamatsu K, Fukushima S, Minagawa A, Omodaka T, Hida T, Hatta N, Takata M, Uhara H, Okuyama R, Ihn H. Significance of 5-S-cysteinyldopa as a marker for melanoma. Int J Mol Sci. 2020;21(2):432.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"948_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.molonc.2015.12.008","volume":"10","author":"SK Huang","year":"2016","unstructured":"Huang SK, Hoon DS. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol. 2016;10(3):450\u201363.","journal-title":"Mol Oncol."},{"issue":"22","key":"948_CR5","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1158\/1078-0432.CCR-05-1074","volume":"11","author":"Y Ikuta","year":"2005","unstructured":"Ikuta Y, Nakatsura T, Kageshita T, Fukushima S, Ito S, Wakamatsu K, Baba H, Nishimura Y. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res. 2005;11(22):8079\u201388.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"948_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/CMR.0b013e328335a8c1","volume":"20","author":"R Mouawad","year":"2010","unstructured":"Mouawad R, Spano J, Khayat D. Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res. 2010;20(2):67\u201376.","journal-title":"Melanoma Res."},{"issue":"6","key":"948_CR7","first-page":"563","volume":"9","author":"KK Jain","year":"2007","unstructured":"Jain KK. Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther. 2007;9(6):563\u201371.","journal-title":"Curr Opin Mol Ther."},{"issue":"11","key":"948_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"G Calin","year":"2006","unstructured":"Calin G, Croce C. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857\u201366.","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"948_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher A, Slack F. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259\u201369.","journal-title":"Nat Rev Cancer."},{"issue":"30","key":"948_CR10","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"P Mitchell","year":"2008","unstructured":"Mitchell P, Parkin R, Kroh E, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"948_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jdermsci.2010.12.010","volume":"61","author":"H Kanemaru","year":"2011","unstructured":"Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M, Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61(3):187\u201393.","journal-title":"J Dermatol Sci."},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.12659\/MSM.891327","volume":"20","author":"P Li","year":"2014","unstructured":"Li P, He QY, Luo CQ, Qian LY. Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med Sci Monit. 2014;20:2472\u20137.","journal-title":"Med Sci Monit."},{"issue":"5","key":"948_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/jid.2012.477","volume":"133","author":"G Saldanha","year":"2013","unstructured":"Saldanha G, Potter L, Shendge P, Osborne J, Nicholson S, Yii NW, Varma S, Aslam MI, Elshaw S, Papadogeorgakis E, Howard Pringle J. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. J Invest Dermatol. 2013;133(5):1381\u20134.","journal-title":"J Invest Dermatol."},{"key":"948_CR14","doi-asserted-by":"publisher","unstructured":"Xu SJ, Xu WJ, Zeng Z, et al. MiR-424 functions as potential diagnostic and prognostic biomarker in melanoma. Clin Lab. 2020;66(7) https:\/\/doi.org\/10.7754\/Clin.Lab.2019.190917.","DOI":"10.7754\/Clin.Lab.2019.190917"},{"issue":"14","key":"948_CR15","doi-asserted-by":"publisher","first-page":"12110","DOI":"10.18632\/oncotarget.3661","volume":"6","author":"C Margue","year":"2015","unstructured":"Margue C, Reinsbach S, Philippidou D, Beaume N, Walters C, Schneider JG, Nashan D, Behrmann I, Kreis S. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget. 2015;6(14):12110\u201327.","journal-title":"Oncotarget."},{"issue":"11","key":"948_CR16","doi-asserted-by":"publisher","first-page":"20193","DOI":"10.1002\/jcp.28619","volume":"234","author":"P Sahranavardfard","year":"2019","unstructured":"Sahranavardfard P, Firouzi J, Azimi M, Khosravani P, Heydari R, Emami Razavi A, Dorraj M, Keighobadi F, Ebrahimi M. MicroRNA-203 reinforces stemness properties in melanoma and augments tumorigenesis in vivo. J Cell Physiol. 2019;234(11):20193\u2013205.","journal-title":"J Cell Physiol."},{"issue":"13","key":"948_CR17","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.7150\/jca.18824","volume":"8","author":"M Bai","year":"2017","unstructured":"Bai M, Zhang H, Si L, Yu N, Zeng A, Zhao R. Upregulation of serum miR-10b is associated with poor prognosis in patients with melanoma. J Cancer. 2017;8(13):2487\u201391.","journal-title":"J Cancer."},{"issue":"9","key":"948_CR18","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.18632\/oncotarget.3142","volume":"6","author":"S Ono","year":"2015","unstructured":"Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DSB. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6(9):7053\u201364.","journal-title":"Oncotarget."},{"issue":"4","key":"948_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/CMR.0000000000000450","volume":"28","author":"L Tengda","year":"2018","unstructured":"Tengda L, Shuping L, Mingli G, Jie G, Yun L, Weiwei Z, Anmei D. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res. 2018;28(4):295\u2013303.","journal-title":"Melanoma Res."},{"issue":"3","key":"948_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/pcmr.12343","volume":"28","author":"V Tembe","year":"2015","unstructured":"Tembe V, Schramm SJ, Stark MS, Patrick E, Jayaswal V, Tang YH, Barbour A, Hayward NK, Thompson JF, Scolyer RA, Yang YH, Mann GJ. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell Melanoma Res. 2015;28(3):254\u201366.","journal-title":"Pigment Cell Melanoma Res."},{"issue":"6","key":"948_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3109\/1354750X.2013.816777","volume":"18","author":"E Greenberg","year":"2013","unstructured":"Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levy D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013;18(6):502\u20138.","journal-title":"Biomarkers."},{"issue":"1","key":"948_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/cancers11010070","volume":"11","author":"C Sol\u00e9","year":"2019","unstructured":"Sol\u00e9 C, Tramonti D, Schramm M, Goicoechea I, Armesto M, Hernandez L, Manterola L, Fernandez-Mercado M, Mujika K, Tuneu A, Jaka A, Tellaetxe M, Friedl\u00e4nder M, Estivill X, Piazza P, Ortiz-Romero P, Middleton M, Lawrie C. The circulating transcriptome as a source of biomarkers for melanoma. Cancers. 2019;11(1):70.","journal-title":"Cancers."},{"issue":"5","key":"948_CR23","doi-asserted-by":"publisher","first-page":"101042831770164","DOI":"10.1177\/1010428317701646","volume":"39","author":"S Fogli","year":"2017","unstructured":"Fogli S, Polini B, Carpi S, Pardini B, Naccarati A, Dubbini N, Lanza M, Breschi MC, Romanini A, Nieri P. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol. 2017;39(5):1010428317701646.","journal-title":"Tumour Biol."},{"issue":"3","key":"948_CR24","first-page":"3097","volume":"8","author":"R Tian","year":"2015","unstructured":"Tian R, Liu T, Qiao L, Gao M, Li J. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. Int J Clin Exp Pathol. 2015;8(3):3097\u2013103.","journal-title":"Int J Clin Exp Pathol."},{"issue":"6","key":"948_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/bjc.2017.477","volume":"118","author":"R Van Laar","year":"2018","unstructured":"Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer. 2018;118(6):857\u201366.","journal-title":"Br J Cancer."},{"issue":"8","key":"948_CR26","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.7150\/thno.18835","volume":"7","author":"W Guo","year":"2017","unstructured":"Guo W, Wang H, Yang Y, Guo S, Zhang W, Liu Y, Yi X, Ma J, Zhao T, Liu L, Jian Z, Liu L, Wang G, Gao T, Shi Q, Li C. Down-regulated miR-23a contributes to the metastasis of cutaneous melanoma by promoting autophagy. Theranostics. 2017;7(8):2231\u201349.","journal-title":"Theranostics."},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1471-2407-10-262","volume":"10","author":"P Leidinger","year":"2010","unstructured":"Leidinger P, Keller A, Borries A, Reichrath J, Rass K, Jager SU, Lenhof HP, Meese E. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer. 2010;10:262.","journal-title":"BMC Cancer."},{"issue":"5","key":"948_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/CMR.0b013e328363e485","volume":"23","author":"R Shiiyama","year":"2013","unstructured":"Shiiyama R, Fukushima S, Jinnin M, Yamashita J, Miyashita A, Nakahara S, Kogi A, Aoi J, Masuguchi S, Inoue Y, Ihn H. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013;23(5):366\u201372.","journal-title":"Melanoma Res."},{"issue":"1","key":"948_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cncr.28981","volume":"121","author":"NH Fleming","year":"2015","unstructured":"Fleming NH, Zhong J, da Silva IP, Vega-Saenz de Miera E, Brady B, Han SW, Hanniford D, Wang J, Shapiro RL, Hernando E, Osman I. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015;121(1):51\u20139.","journal-title":"Cancer."},{"issue":"1","key":"948_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2340\/00015555-2156","volume":"96","author":"V Armand-Labit","year":"2016","unstructured":"Armand-Labit V, Meyer N, Casanova A, Bonnabau H, Platzer V, Tournier E, Sansas B, Verdun S, Thouvenot B, Hilselberger B, Doncescu A, Lamant L, Lacroix-Triki M, Favre G, Pradines A. Identification of a circulating microRNA profile as a biomarker of metastatic cutaneous melanoma. Acta Derm Venereol. 2016;96(1):29\u201334.","journal-title":"Acta Derm Venereol."},{"key":"948_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1479-5876-10-155","volume":"10","author":"EB Friedman","year":"2012","unstructured":"Friedman EB, Shang S, de Miera EV, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med. 2012;10:155.","journal-title":"J Transl Med."},{"issue":"7","key":"948_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ebiom.2015.05.011","volume":"2","author":"MS Stark","year":"2015","unstructured":"Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. EBioMedicine. 2015;2(7):671\u201380.","journal-title":"EBioMedicine."},{"issue":"1","key":"948_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2019.11.010","volume":"97","author":"S Nakahara","year":"2020","unstructured":"Nakahara S, Fukushima S, Okada E, Morinaga J, Kubo Y, Tokuzumi A, Matsumoto S, Tsuruta-Kadohisa M, Kimura T, Kuriyama H, Miyashita A, Kajihara I, Jinnin M, Ihn H. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. J Dermatol Sci. 2020;97(1):77\u20139.","journal-title":"J Dermatol Sci."},{"issue":"11","key":"948_CR34","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3390\/cancers12113361","volume":"12","author":"MA Bustos","year":"2020","unstructured":"Bustos MA, Gross R, Rahimzadeh N, Cole H, Tran LT, Tran KD, Takeshima L, Stern SL, O\u2019Day S, Hoon DSB. A pilot study comparing the efficacy of lactate dehydrogenase levels versus circulating cell-free microRNAs in monitoring responses to checkpoint inhibitor immunotherapy in metastatic melanoma patients. Cancers. 2020;12(11):3361.","journal-title":"Cancers."},{"issue":"6","key":"948_CR35","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/cancers12061692","volume":"12","author":"MA Bustos","year":"2020","unstructured":"Bustos MA, Tran KD, Rahimzadeh N, Gross R, Lin SY, Shoji Y, Murakami T, Boley CL, Tran LT, Cole H, Kelly DF, O\u2019Day S, Hoon DSB. Integrated assessment of circulating cell-free microRNA signatures in plasma of patients with melanoma brain metastasis. Cancers. 2020;12(6):1692.","journal-title":"Cancers."},{"issue":"9","key":"948_CR36","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/15384047.2015.1046021","volume":"16","author":"M Ragusa","year":"2015","unstructured":"Ragusa M, Barbagallo C, Statello L, Caltabiano R, Russo A, Puzzo L, Avitabile T, Longo A, Toro MD, Barbagallo D, Valadi H, di Pietro C, Purrello M, Reibaldi M. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: pathological and diagnostic implications. Cancer Biol Ther. 2015;16(9):1387\u201396.","journal-title":"Cancer Biol Ther."},{"issue":"6","key":"948_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.8.6.12","volume":"8","author":"MS Stark","year":"2019","unstructured":"Stark MS, Gray ES, Isaacs T, Chen FK, Millward M, McEvoy A, Zaenker P, Ziman M, Soyer HP, Glasson WJ, Warrier SK, Stark AL, Rolfe OJ, Palmer JM, Hayward NK. A panel of circulating microRNAs detects uveal melanoma with high precision. Transl Vis Sci Technol. 2019;8(6):12.","journal-title":"Transl Vis Sci Technol."},{"key":"948_CR38","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fgene.2019.00626","volume":"10","author":"M Cui","year":"2019","unstructured":"Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R, Zhang X. Circulating microRNAs in cancer: potential and challenge. Front Genet. 2019;10:626.","journal-title":"Front Genet."},{"issue":"1","key":"948_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/14737159.2020.1696194","volume":"20","author":"S Carpi","year":"2020","unstructured":"\u2022\u2022 Carpi S, Polini B, Fogli S, Podest\u00e0 A, Yl\u00f6sm\u00e4ki E, Cerullo V, Romanini A, Nieri P. Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma. Expert Rev Mol Diagn. 2020;20(1):19\u201330. This review has summarized the previously reported circulating miRNAs as biomarkers for early diagnosis of melanoma","journal-title":"Expert Rev Mol Diagn."},{"issue":"10","key":"948_CR40","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.3390\/cancers12102914","volume":"12","author":"A Sacco","year":"2020","unstructured":"\u2022\u2022 Sacco A, Forgione L, Carotenuto M, de Luca A, Ascierto PA, Botti G, Normanno N. Circulating tumor DNA testing opens new perspectives in melanoma management. Cancers. 2020;12(10):2914. This review has summarized the application of cell free DNA from melanoma patients","journal-title":"Cancers."},{"issue":"10","key":"948_CR41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","volume":"15","author":"L Cabel","year":"2018","unstructured":"Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, Pierga JY, Bidard FC. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018;15(10):639\u201350.","journal-title":"Nat Rev Clin Oncol."},{"key":"948_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre L, Warburton L, Millward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62\u20139.","journal-title":"Cancer Lett."},{"issue":"13","key":"948_CR43","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"SJ Dawson","year":"2013","unstructured":"Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199\u2013209.","journal-title":"N Engl J Med."},{"issue":"8","key":"948_CR44","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","volume":"10","author":"E Crowley","year":"2013","unstructured":"Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472\u201384.","journal-title":"Nat Rev Clin Oncol."},{"issue":"39","key":"948_CR45","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JHJ, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318.","journal-title":"Oncotarget."},{"issue":"30","key":"948_CR46","doi-asserted-by":"publisher","first-page":"48832","DOI":"10.18632\/oncotarget.9453","volume":"7","author":"F Cheng","year":"2016","unstructured":"Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7(30):48832\u201341.","journal-title":"Oncotarget."},{"issue":"5","key":"948_CR47","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548\u201354.","journal-title":"Nat Med."},{"issue":"9","key":"948_CR48","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz Jr LA. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985\u201390.","journal-title":"Nat Med."},{"issue":"1","key":"948_CR49","doi-asserted-by":"publisher","first-page":"10426","DOI":"10.1038\/s41598-019-47030-w","volume":"9","author":"N Iwahashi","year":"2019","unstructured":"Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, Toujima S, Nishio K, Ino K. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing. Sci Rep. 2019;9(1):10426.","journal-title":"Sci Rep."},{"issue":"26","key":"948_CR50","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205\u201311.","journal-title":"J Clin Oncol."},{"issue":"1","key":"948_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297\u2013304.","journal-title":"Clin Chem."},{"key":"948_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cancergen.2020.11.005","volume":"250\u2013251","author":"MA Emelyanova","year":"2021","unstructured":"Emelyanova MA, Telysheva EN, Orlova KV, Ryabaya OO, Snigiryova GP, Abramov IS, Mikhailovich VM. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients. Cancer Genet. 2021;250\u2013251:25\u201335.","journal-title":"Cancer Genet."},{"issue":"6","key":"948_CR53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CMR.0000000000000187","volume":"25","author":"M Gonzalez-Cao","year":"2015","unstructured":"Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25(6):486\u201395.","journal-title":"Melanoma Res."},{"issue":"10","key":"948_CR54","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/exd.13065","volume":"25","author":"AC Knol","year":"2016","unstructured":"Knol AC, Vall\u00e9e A, Herbreteau G, Nguyen JM, Varey E, Gaultier A, Th\u00e9oleyre S, Saint-Jean M, Peuvrel L, Brocard A, Qu\u00e9reux G, Khammari A, Denis MG, Dr\u00e9no B. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline. Exp Dermatol. 2016;25(10):783\u20138.","journal-title":"Exp Dermatol."},{"issue":"1","key":"948_CR55","doi-asserted-by":"publisher","first-page":"18682","DOI":"10.1038\/s41598-020-75792-1","volume":"10","author":"GT Marczynski","year":"2020","unstructured":"Marczynski GT, Laus AC, Dos Reis MB, et al. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Sci Rep. 2020;10(1):18682.","journal-title":"Sci Rep."},{"issue":"1","key":"948_CR56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","volume":"17","author":"T Seremet","year":"2019","unstructured":"Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, el Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, Lienard D, del Marmol V, Heimann P, Neyns B. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.","journal-title":"J Transl Med."},{"issue":"2","key":"948_CR57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jdv.16766","volume":"35","author":"R V\u00e1raljai","year":"2021","unstructured":"V\u00e1raljai R, Elouali S, Lueong SS, Wistuba-Hamprecht K, Seremet T, Siveke JT, Becker JC, Sucker A, Paschen A, Horn PA, Neyns B, Weide B, Schadendorf D, Roesch A. The predictive and prognostic significance of cell-free DNA concentration in melanoma. J Eur Acad Dermatol Venereol. 2021;35(2):387\u201395.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"948_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molonc.2015.09.005","volume":"10","author":"GA Chang","year":"2016","unstructured":"Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol. 2016;10(1):157\u201365.","journal-title":"Mol Oncol."},{"issue":"5","key":"948_CR59","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10147-016-0976-y","volume":"21","author":"A Ashida","year":"2016","unstructured":"Ashida A, Sakaizawa K, Mikoshiba A, Uhara H, Okuyama R. Quantitative analysis of the BRAF (V600E) mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol. 2016;21(5):981\u20138.","journal-title":"Int J Clin Oncol."},{"issue":"1","key":"948_CR60","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1038\/s41598-020-61818-1","volume":"10","author":"J Knuever","year":"2020","unstructured":"Knuever J, Weiss J, Persa OD, Kreuzer K, Mauch C, Hallek M, Schlaak M. The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. Sci Rep. 2020;10(1):4940.","journal-title":"Sci Rep."},{"key":"948_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","volume":"14","author":"M Schreuer","year":"2016","unstructured":"Schreuer M, Meersseman G, Van Den Herrewegen S, et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors. J Transl Med. 2016;14:95.","journal-title":"J Transl Med."},{"key":"948_CR62","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/onco.13926","volume":"26","author":"L Di Guardo","year":"2021","unstructured":"Di Guardo L, Randon G, Corti F, et al. Liquid biopsy and radiological response predict outcomes following discontinuation of targeted therapy in patients with BRAF mutated melanoma. Oncologist. 2021;in press;26:1079\u201384.","journal-title":"Oncologist."},{"issue":"38","key":"948_CR63","doi-asserted-by":"publisher","first-page":"25265","DOI":"10.18632\/oncotarget.25404","volume":"9","author":"G Herbreteau","year":"2018","unstructured":"Herbreteau G, Vall\u00e9e A, Knol AC, Th\u00e9oleyre S, Qu\u00e9reux G, Varey E, Khammari A, Dr\u00e9no B, Denis MG. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265\u201376.","journal-title":"Oncotarget."},{"issue":"1","key":"948_CR64","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1038\/s41598-019-53917-5","volume":"9","author":"RB Forthun","year":"2019","unstructured":"Forthun RB, Hovland R, Schuster C, et al. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Sci Rep. 2019;9(1):17471.","journal-title":"Sci Rep."},{"key":"948_CR65","doi-asserted-by":"publisher","first-page":"11198","DOI":"10.1038\/srep11198","volume":"5","author":"SC Tsao","year":"2015","unstructured":"Tsao SC, Weiss J, Hudson C, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.","journal-title":"Sci Rep."},{"issue":"2","key":"948_CR66","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann Oncol. 2018;29(2):490\u20136.","journal-title":"Ann Oncol."},{"issue":"90","key":"948_CR67","doi-asserted-by":"publisher","first-page":"36238","DOI":"10.18632\/oncotarget.26343","volume":"9","author":"E Long-Mira","year":"2018","unstructured":"Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudi\u00e9 H, Tanga V, All\u00e9gra M, Lespinet-Fabre V, Bordone O, Bonnetaud C, Schiappa R, Butori C, Bence C, Lacour JP, Hofman V, Hofman P. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018;9(90):36238\u201349.","journal-title":"Oncotarget."},{"issue":"1","key":"948_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","volume":"2","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz LA. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014;2(1):42.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"948_CR69","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","volume":"6","author":"MR Girotti","year":"2016","unstructured":"Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KHJ, Saturno G, Furney SJ, Baenke F, Pedersen M, Rogan J, Swan J, Smith M, Fusi A, Oudit D, Dhomen N, Brady G, et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6(3):286\u201399.","journal-title":"Cancer Discov."},{"key":"948_CR70","doi-asserted-by":"crossref","unstructured":"Lin SY, Huang SK, Huynh KT, et al. Multiplex gene profiling of cell-free DNA in patients with metastatic melanoma for monitoring disease. JCO Precis Oncol. 2018;2 PO.17.00225","DOI":"10.1200\/PO.17.00225"},{"issue":"1","key":"948_CR71","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner A, Battke F, Hadaschik D, Schulze M, Wei\u00dfgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, D\u00f6cker D, Biskup S. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180.","journal-title":"J Immunother Cancer."},{"issue":"8","key":"948_CR72","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/cancers12082228","volume":"12","author":"RJ Diefenbach","year":"2020","unstructured":"\u2022 Diefenbach RJ, Lee JH, Menzies AM, Carlino MS, Long GV, Saw RPM, Howle JR, Spillane AJ, Scolyer RA, Kefford RF, Rizos H. Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Cancers. 2020;12(8):2228. This paper has shown comprehensive cfDNA analysis of melanoma using a next-generation sequencing panel based on 30 genes covering driver and targetable mutations","journal-title":"Cancers."},{"issue":"7","key":"948_CR73","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/genes12071080","volume":"12","author":"M Olbryt","year":"2021","unstructured":"Olbryt M, Rajczykowski M, Bal W, Fiszer-Kierzkowska A, Cortez AJ, Mazur M, Suwi\u0144ski R, Wid\u0142ak W. NGS analysis of liquid biopsy (LB) and formalin-fixed paraffin-embedded (FFPE) melanoma samples using Oncomine\u2122 Pan-Cancer Cell-Free Assay. Genes (Basel). 2021;12(7):1080.","journal-title":"Genes (Basel)."},{"issue":"1","key":"948_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/pcmr.12623","volume":"31","author":"TC Gangadhar","year":"2018","unstructured":"Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, Lieberman DB, Soucier D, Fan R, Black TA, Morrissette JJD, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan JB, Xu X, Amaravadi RK, et al. Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res. 2018;31(1):73\u201381.","journal-title":"Pigment Cell Melanoma Res."},{"issue":"3","key":"948_CR75","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jdermsci.2021.04.006","volume":"102","author":"A Kaneko","year":"2021","unstructured":"\u2022 Kaneko A, Kanemaru H, Kajihara I, Mijiddorj T, Miyauchi H, Kuriyama H, Kimura T, Sawamura S, Makino K, Miyashita A, Aoi J, Makino T, Masuguchi S, Fukushima S, Ihn H. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients. J Dermatol Sci. 2021;102(3):158\u201366. This paper has shown the utility of CAPP-Seq analyses in melanoma patients and suggested that MET may be a promising biomarker to monitor the disease status in melanoma patients when treated with BRAF\/MEK inhibitor","journal-title":"J Dermatol Sci."},{"issue":"2","key":"948_CR76","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.canlet.2012.01.020","volume":"342","author":"ES Greenberg","year":"2014","unstructured":"Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DSB. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014;342(2):170\u20137.","journal-title":"Cancer Lett."},{"issue":"2","key":"948_CR77","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/sj.jid.5700073","volume":"126","author":"A Marini","year":"2006","unstructured":"Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol. 2006;126(2):422\u201331.","journal-title":"J Invest Dermatol."},{"issue":"36","key":"948_CR78","doi-asserted-by":"publisher","first-page":"9351","DOI":"10.1200\/JCO.2005.02.9876","volume":"23","author":"T Mori","year":"2005","unstructured":"Mori T, O\u2019Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, Vu VD, Nguyen SL, Hoon DSB. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005;23(36):9351\u20138.","journal-title":"J Clin Oncol."},{"issue":"13","key":"948_CR79","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1158\/0008-5472.CAN-06-0801","volume":"66","author":"T Mori","year":"2006","unstructured":"Mori T, Martinez SR, O\u2019Day SJ, et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006;66(13):6692\u20138.","journal-title":"Cancer Res."},{"issue":"5","key":"948_CR80","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/jid.2012.485","volume":"133","author":"V Hofman","year":"2013","unstructured":"Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol. 2013;133(5):1378\u201381.","journal-title":"J Invest Dermatol."},{"issue":"40","key":"948_CR81","doi-asserted-by":"publisher","first-page":"67355","DOI":"10.18632\/oncotarget.18641","volume":"8","author":"CA Aya-Bonilla","year":"2017","unstructured":"Aya-Bonilla CA, Marsavela G, Freeman JB, Lomma C, Frank MH, Khattak MA, Meniawy TM, Millward M, Warkiani ME, Gray ES, Ziman M. Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget. 2017;8(40):67355\u201368.","journal-title":"Oncotarget."},{"issue":"8","key":"948_CR82","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/jid.2015.127","volume":"135","author":"ES Gray","year":"2015","unstructured":"Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M. Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment. J Invest Dermatol. 2015;135(8):2040\u20138.","journal-title":"J Invest Dermatol."},{"issue":"1","key":"948_CR83","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CMR.0000000000000025","volume":"24","author":"L Khoja","year":"2014","unstructured":"Khoja L, Shenjere P, Hodgson C, Hodgetts J, Clack G, Hughes A, Lorigan P, Dive C. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res. 2014;24(1):40\u20136.","journal-title":"Melanoma Res."},{"issue":"6","key":"948_CR84","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/jid.2012.468","volume":"133","author":"L Khoja","year":"2013","unstructured":"Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013;133(6):1582\u201390.","journal-title":"J Invest Dermatol."},{"key":"948_CR85","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-1-4939-9833-3_11","volume":"2065","author":"F Salvianti","year":"2020","unstructured":"Salvianti F, Costanza F, Sonnati G, et al. Detection and characterization of circulating tumor cells by quantitative real-time PCR. Methods Mol Biol. 2020;2065:139\u201351.","journal-title":"Methods Mol Biol."},{"issue":"7","key":"948_CR86","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1373\/clinchem.2006.081828","volume":"53","author":"L Xi","year":"2007","unstructured":"Xi L, Nicastri DG, El-Hefnawy T, et al. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem. 2007;53(7):1206\u201315.","journal-title":"Clin Chem."},{"issue":"4","key":"948_CR87","first-page":"1497","volume":"9","author":"SR Reynolds","year":"2003","unstructured":"Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res. 2003;9(4):1497\u2013502.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"948_CR88","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/CMR.0b013e32833906b6","volume":"20","author":"I Samija","year":"2010","unstructured":"Samija I, Lukac J, Mari\u0107-Brozi\u0107 J, et al. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res. 2010;20(4):293\u2013302.","journal-title":"Melanoma Res."},{"issue":"7","key":"948_CR89","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ctrv.2013.04.001","volume":"39","author":"W Onstenk","year":"2013","unstructured":"Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev. 2013;39(7):691\u2013700.","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"948_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130418","volume":"10","author":"A Morimoto","year":"2015","unstructured":"Morimoto A, Mogami T, Watanabe M, Iijima K, Akiyama Y, Katayama K, Futami T, Yamamoto N, Sawada T, Koizumi F, Koh Y. High-density dielectrophoretic microwell array for detection, capture, and single-cell analysis of rare tumor cells in peripheral blood. PLoS One. 2015;10(6):e0130418.","journal-title":"PLoS One."},{"issue":"2","key":"948_CR91","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jdermsci.2018.01.011","volume":"90","author":"Y Kiniwa","year":"2018","unstructured":"Kiniwa Y, Nakamura K, Mikoshiba A, Akiyama Y, Morimoto A, Okuyama R. Diversity of circulating tumor cells in peripheral blood: detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis. J Dermatol Sci. 2018;90(2):211\u20133.","journal-title":"J Dermatol Sci."},{"issue":"3","key":"948_CR92","first-page":"325","volume":"137","author":"H Tsao","year":"2001","unstructured":"Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol. 2001;137(3):325\u201330.","journal-title":"Arch Dermatol."},{"issue":"8","key":"948_CR93","first-page":"2253","volume":"60","author":"DS Hoon","year":"2000","unstructured":"Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60(8):2253\u20137.","journal-title":"Cancer Res."},{"key":"948_CR94","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/1471-2407-14-423","volume":"14","author":"D Klinac","year":"2014","unstructured":"Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer. 2014;14:423.","journal-title":"BMC Cancer."},{"issue":"7","key":"948_CR95","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-020-0750-9","volume":"122","author":"CA Aya-Bonilla","year":"2020","unstructured":"Aya-Bonilla CA, Morici M, Hong X, McEvoy AC, Sullivan RJ, Freeman J, Calapre L, Khattak MA, Meniawy T, Millward M, Ziman M, Gray ES. Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. Br J Cancer. 2020;122(7):1059\u201367.","journal-title":"Br J Cancer."},{"issue":"8","key":"948_CR96","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res. 2020;26(8):1886\u201395.","journal-title":"Clin Cancer Res."},{"issue":"10","key":"948_CR97","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1073\/pnas.1719264115","volume":"115","author":"X Hong","year":"2018","unstructured":"Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci USA. 2018;115(10):2467\u201372.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"948_CR98","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 2016;22(3):567\u201374.","journal-title":"Clin Cancer Res."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-022-00948-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T03:57:51Z","timestamp":1666583871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-022-00948-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s11864-022-00948-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}